Journal of Hematology
Scope & Guideline
Connecting Scholars, Enhancing Practice
Introduction
Aims and Scopes
- Clinical Research in Hematological Malignancies:
The journal publishes studies related to various hematological malignancies, including leukemia, lymphoma, and myeloma, focusing on clinical trials, treatment outcomes, and novel therapeutic strategies. - Transfusion Medicine and Hemostasis:
Research on blood transfusion practices, management of bleeding disorders, and the role of hemostatic agents is a core area, addressing both clinical and laboratory aspects. - Genetics and Molecular Biology in Hematology:
The journal emphasizes the genetic and molecular underpinnings of hematological diseases, including studies on mutations, genetic predispositions, and the role of biomarkers in diagnosis and treatment. - Patient-Centered Outcomes and Quality of Life:
An important aim is to evaluate the impact of hematological diseases and their treatments on patients' quality of life, including psychosocial factors and adherence to therapy. - Innovative Therapeutics and Clinical Trials:
The journal highlights cutting-edge therapeutic modalities, including CAR-T cell therapy, monoclonal antibodies, and gene therapies, along with the results of clinical trials and real-world studies. - Epidemiology and Health Disparities:
Research that explores the epidemiological aspects of hematological disorders, including disease prevalence, outcomes across different populations, and health disparities.
Trending and Emerging
- Immunotherapy and CAR-T Cell Therapies:
There is a significant increase in publications focusing on immunotherapy, including CAR-T cell therapies for hematological malignancies, highlighting their rapid development and clinical application. - Real-World Evidence and Patient Registries:
An upward trend in studies utilizing real-world data and patient registries is evident, providing insights into treatment outcomes and effectiveness in diverse populations. - Genomic and Molecular Profiling:
Research focusing on the genomic and molecular characterization of hematological diseases is on the rise, emphasizing the importance of personalized medicine and targeted therapies. - Management of COVID-19 in Hematology Patients:
Emerging studies addressing the impact of COVID-19 on patients with hematological disorders, including vaccination responses and treatment adaptations, are increasingly prevalent. - Health Disparities and Patient-Centered Care:
There is a growing emphasis on understanding health disparities in hematology, with research focusing on social determinants of health and their impact on patient outcomes. - Chronic Conditions and Comorbidities:
An increasing focus on the management of chronic conditions and comorbidities among patients with hematological diseases is evident, particularly in the context of aging populations.
Declining or Waning
- Traditional Chemotherapy Approaches:
There is a noticeable decrease in publications focusing solely on traditional chemotherapy regimens for hematological malignancies as newer targeted therapies and immunotherapies gain prominence. - Basic Hematology Education:
Research articles centered on basic hematology education and training have diminished, possibly due to a shift towards more advanced and specialized topics that incorporate new technologies and treatment modalities. - Longitudinal Studies of Established Treatments:
Fewer studies are being published that focus on long-term outcomes associated with established treatments, as the emphasis shifts towards innovative therapies and their immediate effects. - Hematopathology Techniques:
The publication of studies focused solely on traditional hematopathology techniques has decreased, reflecting a move towards molecular and genetic diagnostics that utilize advanced technologies. - Single-Agent Therapies:
Research specifically on single-agent therapies is declining in favor of studies on combination therapies and novel treatment strategies that show improved efficacy.
Similar Journals
UHOD-Uluslararasi Hematoloji-Onkoloji Dergisi
Empowering researchers with pivotal findings.UHOD-Uluslararasi Hematoloji-Onkoloji Dergisi, published by AKAD DOKTORLAR YAYINEVI, is a pivotal journal in the fields of hematology and oncology, catering to an international audience of researchers, clinicians, and students. Since its inception in 2005, the journal has committed to disseminating high-quality, peer-reviewed research, highlighting advancements and challenges in the diagnosis and treatment of hematological and oncological disorders. Registered under ISSN 1306-133X, it serves as a significant platform for scholarly discourse, despite its recent categorization in the Q4 quartile for both hematology and oncology—indicating opportunities for growth and contribution within the scientific community. While currently not Open Access, the journal's indexed contribution to Scopus ranks it within the 12th and 17th percentiles in the domains of hematology and oncology respectively, reflecting its emerging presence within the academic landscape. As it approaches its convergence point in 2024, UHOD strives to elevate its influence, providing invaluable insights and fostering collaborations in the ongoing fight against blood disorders and cancer.
Therapeutic Advances in Hematology
Pioneering breakthroughs in blood health.Therapeutic Advances in Hematology is a prestigious, peer-reviewed journal dedicated to advancing the field of hematology through innovative research and clinical studies. Published by SAGE Publications Ltd, this journal has become a vital resource for hematology professionals and researchers since its inception in 2010. With its impactful Q1 ranking in Hematology and a Scopus rank of 62 out of 137, it firmly establishes itself as a leader in disseminating significant findings and therapeutic approaches. The journal has been committed to open access since 2019, ensuring that its cutting-edge research is readily available to the global scientific community. Covering a broad scope of topics within hematology, Therapeutic Advances in Hematology is an essential platform for those seeking to enhance their understanding and implementation of therapeutic practices in hematological conditions. The journal embraces submissions from both clinical and laboratory perspectives, fostering collaboration and dialogue among researchers, clinicians, and students alike.
LEUKEMIA & LYMPHOMA
Fostering innovation in cancer diagnostics and therapies.LEUKEMIA & LYMPHOMA is a prestigious peer-reviewed journal published by Taylor & Francis Ltd, focusing on vital research in the fields of hematology, oncology, and cancer research. With an ISSN of 1042-8194 and an E-ISSN of 1029-2403, this journal is recognized for its high-quality and impactful contributions to understanding blood cancers, with a notable impact factor reflective of its influence. Since its inception in 1989, LEUKEMIA & LYMPHOMA has continuously provided a platform for researchers and professionals to disseminate their findings, fostering advancements in diagnostic, therapeutic, and clinical strategies related to leukemias and lymphomas. The journal ranks in the Q2 category for both Hematology and Oncology research categories as of 2023, underscoring its commitment to excellence. The journal is based in the United Kingdom and serves a global audience, making it an essential resource for those dedicated to improving outcomes for patients with hematological malignancies.
CANCER JOURNAL
Fostering Collaboration in the Fight Against Cancer.CANCER JOURNAL is a leading peer-reviewed publication dedicated to the dissemination of innovative research in the fields of cancer research and oncology. Published by Lippincott Williams & Wilkins, this journal serves as an essential resource for researchers, clinicians, and students seeking to advance their understanding of cancer mechanisms, treatment strategies, and patient care. With an ISSN of 1528-9117 and an E-ISSN of 1540-336X, it boasts a respectable 2023 Q2 category ranking in both Cancer Research and Oncology, reflecting its impactful contributions to the scientific community. Although it currently does not offer open access, the journal's rigorous peer-review process ensures the publication of high-quality, relevant studies that stimulate further investigation and collaboration among professionals. Since its inception, the journal has evolved through several converged years, maintaining a steadfast commitment to addressing the complexities of cancer biology and treatment. At its core, CANCER JOURNAL aims to foster advancements in oncology, making it a vital platform for sharing pivotal findings that could transform cancer research and therapeutic practices.
PEDIATRIC HEMATOLOGY AND ONCOLOGY
Transforming pediatric care with expert insights and research.Pediatric Hematology and Oncology, published by Taylor & Francis Inc, serves as a vital platform dedicated to the fields of hematology, oncology, and pediatrics, providing a comprehensive avenue for the dissemination of scholarly research and clinical advancements. With an ISSN of 0888-0018 and an E-ISSN of 1521-0669, this journal has successfully converged its expertise over the years from 1984 to 2024. Ranked in the Q3 category for Hematology and Oncology, alongside a Q2 ranking in Pediatrics, Perinatology, and Child Health (2023), it engages a diverse readership comprising researchers, healthcare professionals, and students eager to explore groundbreaking studies in child health and treatment methodologies. While it currently does not offer Open Access options, the journal is widely cited and recognized, particularly in its specialized fields, fostering a rich environment for dialogue and innovation in the management of pediatric hematological and oncological disorders. The journal is based in the United Kingdom at 530 Walnut Street, Ste 850, Philadelphia, PA 19106, making it an essential resource for those pursuing excellence in pediatric medical research.
BLOOD REVIEWS
Connecting professionals through cutting-edge research.BLOOD REVIEWS is a highly regarded journal published by Churchill Livingstone, specializing in the fields of Hematology and Oncology. With an impressive Q1 ranking in both disciplines and placing in the top 10% of its peer categories according to Scopus metrics, it provides an essential platform for the dissemination of cutting-edge research and reviews pertaining to blood disorders and cancer treatment. Since its inception in 1987 and continuing through 2024, the journal has established itself as a cornerstone for healthcare professionals, researchers, and students who seek to advance their understanding of hematologic and oncologic topics. While not an open-access journal, BLOOD REVIEWS retains a reputation for delivering high-quality, peer-reviewed articles that foster dialogue and innovation within the scientific community. For those in the United States and beyond, the journal serves as a vital resource, housed at the Journal Production Department in Edinburgh, Scotland, ensuring accessibility and a global reach in its critical academic contributions.
Blood Advances
Shaping the Landscape of Hematology ResearchBlood Advances is a premier, peer-reviewed journal published by Elsevier, dedicated to the field of hematology. With an impressive impact factor and classified within the Q1 category of hematology for 2023, it ranks as the 16th out of 137 journals in the Scopus Medicine Hematology category, placing it in the top 88th percentile globally. This influential journal, which has been disseminating invaluable research since its inception in 2017, focuses on advancing knowledge and innovation in blood science, including clinical and laboratory aspects of hematology. Although it offers limited open access features, its comprehensive scope encompasses various topics relevant to both researchers and practitioners. Located in the United States and managed from Amsterdam, Blood Advances provides a vital platform for the dissemination of groundbreaking research, making significant contributions to the understanding and treatment of blood disorders. Researchers, professionals, and students alike will find this journal an essential resource for keeping abreast of the latest developments and advancements in hematology.
CURRENT OPINION IN HEMATOLOGY
Empowering clinicians and researchers with cutting-edge insights.CURRENT OPINION IN HEMATOLOGY is a leading peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the latest advancements and insights in the field of hematology. With an impressive impact factor and ranked in the first quartile (Q1) of its category, this journal serves as a vital resource for researchers, clinicians, and students seeking to stay informed on contemporary issues and emerging trends in hematological research and treatment. Established in 1994, it showcases critical reviews, expert commentary, and systematic analyses across a broad spectrum of hematology topics, contributing significantly to clinical and experimental knowledge through its robust editorial standards. While offering traditional subscription access, CURRENT OPINION IN HEMATOLOGY remains committed to providing a platform that bridges the gap between fundamental research and clinical application, making it indispensable for professionals dedicated to advancing patient care and scientific understanding in hematology.
Indian Journal of Hematology and Blood Transfusion
Fostering Collaboration in Hematology and Transfusion MedicineIndian Journal of Hematology and Blood Transfusion, published by SPRINGER INDIA, serves as a leading platform for disseminating original research, reviews, and case studies in the field of hematology. With an ISSN of 0971-4502 and E-ISSN 0974-0449, this journal has been instrumental in advancing knowledge from 2000 to 2024, providing insights into critical issues surrounding blood disorders and transfusion practices. Currently ranked in the Q3 category for Hematology for 2023, it reflects a commitment to high-quality scientific content amidst a competitive landscape where it ranks 97/137 in Scopus for Medicine - Hematology, placing it in the 29th percentile of its peers. The journal primarily addresses a diverse readership, including researchers, healthcare professionals, and students, aiming to foster innovation and collaboration within the field. Although it operates under a subscription model, access options for individual articles and institutional subscriptions ensure that valuable research is disseminated widely to enhance medical practice and education in hematology.
Blood Cancer Discovery
Catalyzing Change in Cancer Research LandscapesBlood Cancer Discovery is a premier academic journal published by the American Association for Cancer Research, dedicated to advancing the understanding of hematologic malignancies through cutting-edge research in the fields of oncology, biochemistry, and molecular biology. With an impressive impact factor and recognition as a Q1 journal across multiple disciplines, including cancer research and hematology, Blood Cancer Discovery serves as an essential platform for scholars and practitioners alike, facilitating impactful discourse and dissemination of pioneering findings. This open-access journal, established within the vibrant academic landscape of the United States, aims to bridge gaps in research and foster collaborations to ultimately enhance patient outcomes. Its Scopus rankings demonstrate its vital role in the critical advancement of cancer research and therapeutic development. By inviting contributions from a diverse range of disciplines, Blood Cancer Discovery is poised to drive innovation and inspire future advancements in understanding blood cancers.